Thus, terminal UPR branches, PERK/eIF2α/ATF4/CHOP and IRE1/Ask1/JNK/NOXA pathways, conclude to severe GBM lethality, highlighting new therapeutic approaches [148]. This evidence concerns the gene ATF4 and glioblastoma.